Key studies show that six months of Roche's (RHHBY.OB) Herceptin breast-cancer treatment is no...

|About: Roche Holding Ltd ADR (RHHBY)|By:, SA News Editor
Key studies show that six months of Roche's (RHHBY.OB) Herceptin breast-cancer treatment is no more effective than one year's worth - setting aside a downside risk of $1.5B in lost revenue if the shorter term had shown an advantage. But extending treatment to two years also doesn't look worthwhile, putting a cap on Roche's ability to squeeze out more from the drug before a 2014 patent expiration. RHHBY.OB +0.8% premarket.